Eyncus Pharmaceuticals And Healthcare Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 50.00 K
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -41.19%
- Profit Growth 88.14%
- Ebitda 88.47%
- Net Worth -7.32%
- Total Assets 41.02%
About Eyncus Pharmaceuticals And Healthcare
Eyncus Pharmaceuticals And Healthcare Private Limited (EPAHPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 March 2019 (Five years and 11 months 3 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 50.00 K , as per Ministry of Corporate Affairs (MCA) records.
Anupam Tiwari and Anurag Tiwari serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230UP2019PTC114716
-
Company No.
114716
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Mar 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Eyncus Pharmaceuticals And Healthcare?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anurag Tiwari
|
Director | 05-Oct-2021 | Current |
|
Anupam Tiwari
|
Director | 15-Mar-2019 | Current |
Financial Performance of Eyncus Pharmaceuticals And Healthcare.
Eyncus Pharmaceuticals And Healthcare Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 41.19% decrease. The company also saw a substantial improvement in profitability, with a 88.14% increase in profit. The company's net worth dipped by a decrease of 7.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eyncus Pharmaceuticals And Healthcare?
In 2023, Eyncus Pharmaceuticals And Healthcare had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Raysense Private LimitedAnurag Tiwari is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Eyncus Pharmaceuticals And Healthcare?
Unlock and access historical data on people associated with Eyncus Pharmaceuticals And Healthcare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eyncus Pharmaceuticals And Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eyncus Pharmaceuticals And Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
